Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Consensus Best Practices for Neoadjuvant Therapy in Pancreatic Cancer

    A panel of 47 North American experts has developed 82 consensus best practices for delivering neoadjuvant therapy in pancreatic ductal adenocarcinoma, using a modified Delphi process to standardize and optimize care. This effort aims to improve treatment approaches, reduce variability in care, and enhance patient outcomes. The study outlines best practices across the entire neoadjuvant…

    2025.02.06
  • NCCN Breast Cancer Guidelines (Version 3.2024): Advancing Multidisciplinary Care

    The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer provide essential recommendations for managing carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer,…

    2025.02.06
  • Immunohistochemical Status Predicts Response to Neoadjuvant Therapy in HER2+ Breast Cancer

    In December 2024 a publication in the Annals of Surgical Oncology analyzed data from the National Cancer Database, showing that HER2 IHC3+ patients had significantly higher pathologic complete response (pCR)…

    2025.02.06
  • Advancing Immunotherapy in Refractory Colorectal Cancer

    In the pursuit of improving outcomes for patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC), Dr. Filippo Pietrantonio has made significant contributions through groundbreaking research exploring the potential of combining vorbipiprant, a prostaglandin EP4 antagonist, with PD-1 blockade therapy.

    2025.02.05
  • Exploring Real-World Outcomes in BRAF V600E-Mutated Metastatic Colorectal Cancer

    This real-world study sheds light on the clinical outcomes of patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI). Conducted across Spain and Italy, the study evaluated 26 patients, offering valuable insights into survival outcomes and treatment-related adverse events in routine clinical practice.

    2025.02.05
  • SEOM-GEMCAD-TTD Clinical Guidelines for the Adjuvant Treatment of Colon Cancer (2023)

    The latest SEOM-GEMCAD-TTD clinical guidelines offer comprehensive updates on the adjuvant treatment of colon cancer, emphasizing the importance of personalized therapeutic strategies to optimize patient outcomes. These guidelines provide evidence-based recommendations tailored to tumor stage, molecular characteristics, and patient-specific factors, highlighting the shift towards precision medicine in oncology.

    2025.02.05
  • ESMO China Highlights | Dr. Yanhong Deng: Bispecific Antibody Ivonescimab Offers a New Option for Personalized Treatment of MSS mCRC

    Oncology Frontier: Could you briefly introduce the current first-line treatment landscape for mCRC and the background of your study design? Dr. Yanhong Deng: The first-line treatment strategy for mCRC is…

    2025.02.05
  • Dr. Yong Zeng: Sharing the Experience of Perioperative ERAS Application in Liver Resection at West China Hospital

    1. What Can ERAS Bring to Surgical Care? A meta-analysis published in Clinical Nutrition explored the differences in outcomes between patients undergoing major elective open colorectal surgery under the ERAS…

    2025.02.05
«previous next»
Recent Posts
  • 2026 Xianghu Breast Cancer Treatment Frontiers Conference | Professor Zhanhong Chen: Cardio-Oncology Supports Comprehensive Breast Cancer Care, While ADCs Reshape Treatment for Advanced HER2-Positive Disease
  • 2026 Xianghu Breast Cancer Treatment Frontiers Conference | Professor Hai Hu: Advancing Precision Medicine and Exploring New Approaches to Breast Cancer Care
  • 2026 Xianghu Breast Cancer Treatment Frontiers Conference | Professor Xiaojia Wang: Integrating Guideline Outreach with Academic Forums to Advance Standardized and Equitable Breast Cancer Care
  • 2026 East China Breast Cancer Salon | Professor Michael Gnant: Neoadjuvant Therapy Is Reshaping Breast Surgery, While China-Europe Collaboration Opens New Pathways in Care
  • 2026 East China Breast Cancer Salon | Professor Zefei Jiang: Strengthening Regional Academic Exchange to Foster the Growth of Chinese Oncology Research
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top